{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:22:14Z","timestamp":1791894134657,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:00:00Z","timestamp":1434067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00281-015-0502-8","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T12:13:01Z","timestamp":1434024781000},"page":"413-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Pathogenesis of Beh\u00e7et\u2019s disease: autoinflammatory features and beyond"],"prefix":"10.1007","volume":"37","author":[{"given":"Ahmet","family":"G\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"issue":"4 Suppl 60","key":"502_CR1","first-page":"S2","volume":"28","author":"H Behcet","year":"2010","unstructured":"Behcet H, Matteson EL (2010) On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol 28(4 Suppl 60):S2\u2013S5","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"502_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"issue":"1","key":"502_CR3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","volume":"4","author":"A Gul","year":"2005","unstructured":"Gul A (2005) Beh\u00e7et\u2019s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4(1):81\u201383","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"8","key":"502_CR4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","volume":"3","author":"D McGonagle","year":"2006","unstructured":"McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3(8), e297","journal-title":"PLoS Med"},{"issue":"4 Suppl 38","key":"502_CR5","first-page":"S1","volume":"23","author":"H Yazici","year":"2005","unstructured":"Yazici H, Fresko I (2005) Beh\u00e7et\u2019s disease and other autoinflammatory conditions: what\u2019s in a name? Clin Exp Rheumatol 23(4 Suppl 38):S1\u2013S2","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 67","key":"502_CR6","first-page":"S3","volume":"29","author":"A Gul","year":"2011","unstructured":"Gul A (2011) Genome-wide association studies in Beh\u00e7et\u2019s disease: expectations and promises. Clin Exp Rheumatol 29(4 Suppl 67):S3\u2013S5","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"502_CR7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","volume":"97","author":"MF McDermott","year":"1999","unstructured":"McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97(1):133\u2013144","journal-title":"Cell"},{"issue":"6","key":"502_CR8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","volume":"140","author":"DL Kastner","year":"2010","unstructured":"Kastner DL, Aksentijevich I, Goldbach-Mansky R (2010) Autoinflammatory disease reloaded: a clinical perspective. Cell 140(6):784\u2013790","journal-title":"Cell"},{"issue":"4","key":"502_CR9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","volume":"162","author":"PM Ridker","year":"2011","unstructured":"Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162(4):597\u2013605","journal-title":"Am Heart J"},{"issue":"9","key":"502_CR10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","volume":"32","author":"CM Larsen","year":"2009","unstructured":"Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32(9):1663\u20131668","journal-title":"Diabetes Care"},{"issue":"9881","key":"502_CR11","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","volume":"381","author":"A Moran","year":"2013","unstructured":"Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381(9881):1905\u20131915","journal-title":"Lancet"},{"key":"502_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","volume":"65","author":"AA Jesus","year":"2014","unstructured":"Jesus AA, Goldbach-Mansky R (2014) IL-1 blockade in autoinflammatory syndromes. Annu Rev Med 65:223\u2013244","journal-title":"Annu Rev Med"},{"issue":"6","key":"502_CR13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/ard.2006.068841","volume":"66","author":"I Kone-Paut","year":"2007","unstructured":"Kone-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I (2007) Autoinflammatory gene mutations in Beh\u00e7et\u2019s disease. Ann Rheum Dis 66(6):832\u2013834","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"502_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4291\/wjgp.v5.i3.228","volume":"5","author":"V Yazisiz","year":"2014","unstructured":"Yazisiz V (2014) Similarities and differences between Beh\u00e7et\u2019s disease and Crohn\u2019s disease. World J Gastrointest Pathophysiol 5(3):228\u2013238","journal-title":"World J Gastrointest Pathophysiol"},{"key":"502_CR15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621\u2013668","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"502_CR16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/ard.59.8.622","volume":"59","author":"A Gul","year":"2000","unstructured":"Gul A, Inanc M, Ocal L, Aral O, Konice M (2000) Familial aggregation of Beh\u00e7et\u2019s disease in Turkey. Ann Rheum Dis 59(8):622\u2013625","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"502_CR17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M Menthon de","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A (2009) HLA-B51\/B5 and the risk of Beh\u00e7et\u2019s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61(10):1287\u20131296","journal-title":"Arthritis Rheum"},{"issue":"1","key":"502_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/09273948.2011.634978","volume":"20","author":"A Gul","year":"2012","unstructured":"Gul A, Ohno S (2012) HLA-B*51 and Beh\u00e7et\u2019s disease. Ocular Immunol Inflamm 20(1):37\u201343","journal-title":"Ocular Immunol Inflamm"},{"issue":"6","key":"502_CR19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/rheumatology\/40.6.668","volume":"40","author":"A Gul","year":"2001","unstructured":"Gul A, Uyar FA, Inanc M, Ocal L, Tugal-Tutkun I, Aral O et al (2001) Lack of association of HLA-B*51 with a severe disease course in Beh\u00e7et\u2019s disease. Rheumatology 40(6):668\u2013672","journal-title":"Rheumatology"},{"issue":"5","key":"502_CR20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","volume":"51","author":"C Maldini","year":"2012","unstructured":"Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Beh\u00e7et\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology 51(5):887\u2013900","journal-title":"Rheumatology"},{"issue":"8","key":"502_CR21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et\u2019s disease. Nat Genet 42(8):698\u2013702","journal-title":"Nat Genet"},{"issue":"8","key":"502_CR22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T et al (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et\u2019s disease susceptibility loci. Nat Genet 42(8):703\u2013706","journal-title":"Nat Genet"},{"issue":"1","key":"502_CR23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0000000000000003","volume":"26","author":"A Gul","year":"2014","unstructured":"Gul A (2014) Genetics of Beh\u00e7et\u2019s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol 26(1):56\u201363","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"502_CR24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ng.2551","volume":"45","author":"T Hughes","year":"2013","unstructured":"Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Duzgun N et al (2013) Identification of multiple independent susceptibility loci in the HLA region in Beh\u00e7et\u2019s disease. Nat Genet 45(3):319\u2013324","journal-title":"Nat Genet"},{"issue":"2","key":"502_CR25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ng.2520","volume":"45","author":"Y Kirino","year":"2013","unstructured":"Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E et al (2013) Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et\u2019s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45(2):202\u2013207","journal-title":"Nat Genet"},{"issue":"24","key":"502_CR26","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.1073\/pnas.1406575111","volume":"111","author":"MJ Ombrello","year":"2014","unstructured":"Ombrello MJ, Kirino Y, de Bakker PI, Gul A, Kastner DL, Remmers EF (2014) Beh\u00e7et\u2019s disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 111(24):8867\u20138872","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"502_CR27","doi-asserted-by":"crossref","first-page":"19890","DOI":"10.1073\/pnas.1309781110","volume":"110","author":"E Zervoudi","year":"2013","unstructured":"Zervoudi E, Saridakis E, Birtley JR, Seregin SS, Reeves E, Kokkala P et al (2013) Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. Proc Natl Acad Sci U S A 110(49):19890\u201319895","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"502_CR28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.52.11.823","volume":"52","author":"N Dilsen","year":"1993","unstructured":"Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A (1993) Comparative study of the skin pathergy test with blunt and sharp needles in Beh\u00e7et\u2019s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 52(11):823\u2013825","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"502_CR29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2133.1995.tb16946.x","volume":"132","author":"A Gul","year":"1995","unstructured":"Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P (1995) Immunohistology of skin pathergy reaction in Beh\u00e7et\u2019s disease. Br J Dermatol 132(6):901\u2013907","journal-title":"Br J Dermatol"},{"key":"502_CR30","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease. International Study Group for Beh\u00e7et\u2019s Disease. Lancet. 1990;335(8697):1078\u201380."},{"issue":"9","key":"502_CR31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.50.9.634","volume":"50","author":"N Cakir","year":"1991","unstructured":"Cakir N, Yazici H, Chamberlain MA, Barnes CG, Yurdakul S, Atasoy S et al (1991) Response to intradermal injection of monosodium urate crystals in Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 50(9):634\u2013636","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"502_CR32","first-page":"1544","volume":"20","author":"JL Mege","year":"1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20(9):1544\u20131549","journal-title":"J Rheumatol"},{"issue":"5 Suppl 24","key":"502_CR33","first-page":"S6","volume":"19","author":"A Gul","year":"2001","unstructured":"Gul A (2001) Beh\u00e7et\u2019s disease: an update on the pathogenesis. Clin Exp Rheumatol 19(5 Suppl 24):S6\u2013S12","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"502_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40257-014-0092-6","volume":"15","author":"A Alavi","year":"2014","unstructured":"Alavi A, Sajic D, Cerci FB, Ghazarian D, Rosenbach M, Jorizzo J (2014) Neutrophilic dermatoses: an update. Am J Clin Dermatol 15(5):413\u2013423","journal-title":"Am J Clin Dermatol"},{"issue":"20","key":"502_CR35","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1073\/pnas.1306352110","volume":"110","author":"Y Kirino","year":"2013","unstructured":"Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E et al (2013) Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Beh\u00e7et\u2019s disease. Proc Natl Acad Sci U S A 110(20):8134\u20138139","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"502_CR36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A et al (2007) Anti-TNF therapy in the management of Beh\u00e7et\u2019s disease\u2014review and basis for recommendations. Rheumatology 46(5):736\u2013741","journal-title":"Rheumatology"},{"issue":"4 Suppl 84","key":"502_CR37","first-page":"S149","volume":"32","author":"A Arida","year":"2014","unstructured":"Arida A, Sfikakis PP (2014) Anti-cytokine biologic treatment beyond anti-TNF in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 32(4 Suppl 84):S149\u2013S155","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"502_CR38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A Gul","year":"2012","unstructured":"Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A et al (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et\u2019s disease: an open-label pilot study. Ann Rheum Dis 71(4):563\u2013566","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"502_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease. Autoimmun Rev 14(1):1\u20139","journal-title":"Autoimmun Rev"},{"issue":"4","key":"502_CR40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","volume":"44","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Pipitone N, Pazzola G, Salvarani C (2015) Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et. Semin Arthritis Rheum 44(4):472\u2013475","journal-title":"Semin Arthritis Rheum"},{"issue":"4 Suppl 84","key":"502_CR41","first-page":"S54","volume":"32","author":"V Calvo-Rio","year":"2014","unstructured":"Calvo-Rio V, de la Hera D, Beltran-Catalan E, Blanco R, Hernandez M, Martinez-Costa L et al (2014) Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32(4 Suppl 84):S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"502_CR42","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","volume":"52","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hatemi G (2013) Lack of efficacy of tocilizumab in mucocutaneous Beh\u00e7et\u2019s syndrome: report of two cases. Rheumatology 52(10):1923\u20131924","journal-title":"Rheumatology"},{"key":"502_CR43","doi-asserted-by":"crossref","unstructured":"Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, et al. Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab. Clin Rheumatol. 2014","DOI":"10.1007\/s10067-014-2589-z"},{"issue":"3","key":"502_CR44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1046\/j.1365-2249.1997.d01-947.x","volume":"107","author":"S Esin","year":"1997","unstructured":"Esin S, Gul A, Hodara V, Jeddi-Tehrani M, Dilsen N, Konice M et al (1997) Peripheral blood T cell expansions in patients with Beh\u00e7et\u2019s disease. Clin Exp Immunol 107(3):520\u2013527","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"502_CR45","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/bjo.87.10.1264","volume":"87","author":"B Li","year":"2003","unstructured":"Li B, Yang P, Zhou H, Zhang Z, Xie C, Lin X et al (2003) T-bet expression is upregulated in active Beh\u00e7et\u2019s disease. Br J Ophthalmol 87(10):1264\u20131267","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"502_CR46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2249.2004.02688.x","volume":"139","author":"H Nagafuchi","year":"2005","unstructured":"Nagafuchi H, Takeno M, Yoshikawa H, Kurokawa MS, Nara K, Takada E et al (2005) Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Beh\u00e7et\u2019s disease. Clin Exp Immunol 139(2):363\u2013370","journal-title":"Clin Exp Immunol"},{"issue":"3 Suppl 77","key":"502_CR47","first-page":"32","volume":"31","author":"SY Na","year":"2013","unstructured":"Na SY, Park MJ, Park S, Lee ES (2013) Up-regulation of Th17 and related cytokines in Beh\u00e7et\u2019s disease corresponding to disease activity. Clin Exp Rheumatol 31(3 Suppl 77):32\u201340","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"502_CR48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells. Nat Med 18(7):1069\u20131076","journal-title":"Nat Med"},{"issue":"2","key":"502_CR49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27(2):127\u2013133","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"502_CR50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777\u2013787","journal-title":"Ophthalmology"},{"issue":"12","key":"502_CR51","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12):1693\u20131700","journal-title":"Gut"},{"issue":"12","key":"502_CR52","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology 42(12):1539\u20131544","journal-title":"Rheumatology"},{"issue":"3","key":"502_CR53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A et al (2010) Rituximab in intractable ocular lesions of Beh\u00e7et\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13(3):246\u2013252","journal-title":"Int J Rheum Dis"},{"issue":"16","key":"502_CR54","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C et al (2015) Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study. N Engl J Med 372(16):1510\u20131518","journal-title":"N Engl J Med"},{"issue":"4","key":"502_CR55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159(4):842\u2013855","journal-title":"Br J Pharmacol"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-015-0502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-015-0502-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-015-0502-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T14:40:54Z","timestamp":1566830454000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-015-0502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s00281-015-0502-8","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]}}}